Association between plasma brain natriuretic peptide/N-terminal pro-brain natriuretic peptide levels and atrial fibrillation: Evidence from a meta-analysis

Chinese Medical Journal

Volumn 127, Issue 15, 2014, Pages 2824-2828

  Liu, Yao Wu ^a   Xiao, Yun Yun ^b   Chen, Xin Guang ^a   Zhang, Feng Xiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Brain natriuretic peptide; Meta analysis; N terminal pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MEDICAL LITERATURE; META ANALYSIS; PROTEIN POLYMORPHISM; PUBLISHING; SENSITIVITY ANALYSIS; BLOOD;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84905569652     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132834     Document Type: Article

References (33)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-e198.
2. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005; 13: 181-193.
3. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115: 135-143.
4. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
5. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002; 44: 293-321.
6. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004; 6: 269-273.
7. van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, et al. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis 2012; 34: 106-113.
8. Kim H, Jun DW, Cho YK, Nam CW, Han SW, Hur SH, et al. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction. Echocardiography 2008; 25: 961-967.
9. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
10. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000; 35: 1256-1262.
11. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
12. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
16. Ellinor PT, Low AF, Patton KK, Shea MA, Macrae CA. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 2005; 45: 82-86.
17. Shin DI, Jaekel K, Schley P, Sause A, Muller M, Fueth R, et al. Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol 2005; 94: 795-800.
18. Lee SH, Jung JH, Choi SH, Lee N, Park WJ, Oh DJ, et al. Determinants of brain natriuretic peptide levels in patients with lone atrial fibrillation. Circ J 2006; 70: 100-104.
19. Li J, Wang L. B-type natriuretic peptide levels in patients with paroxysmal lone atrial fibrillation. Heart Vessels 2006; 21: 137-140.
20. Corell P, Gustafsson F, Kistorp C, Madsen LH, Schou M, Hildebrandt P. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 2007; 117: 395-402.
21. Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P, et al. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest 2008; 133: 1203-1208.
22. Bai M, Yang J, Li Y. Serum N-terminal-pro-brain natriuretic peptide level and its clinical implications in patients with atrial fibrillation. Clin Cardiol 2009; 32: E1-E5.
23. Letsas KP, Filippatos GS, Pappas LK, Mihas CC, Markou V, Alexanian IP, et al. Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol 2009; 98: 101-106.
24. Ulimoen SR, Enger S, Tveit A. Impact of atrial fibrillation on NT-proBNP levels in a 75-year-old population. Scand J Clin Lab Invest 2009; 69: 579-584.
25. Dogan A, Gedikli O, Ozaydin M, Acar G. Plasma renin activity and pro-B-type natriuretic peptide levels in different atrial fibrillation types. Anadolu Kardiyol Derg 2010; 10: 317-322.
26. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011; 13: 1110-1117.
27. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013; 15: 486-493.
28. Wu N, Xu B, Xiang Y, Wu L, Zhang Y, Ma X, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol 2013; 169: 62-72.
29. Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991; 69: 1500-1506.
30. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6: 92-96.
31. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167.
32. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005; 11: S81-S83.
33. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.